Febuxostat is a potent xanthine oxidase inhibitor used as a first-line treatment for hyperuricemia in patients with gout. While the brand-name drug Feburic® is widely established, the availability of generic alternatives is crucial for improving patient access and reducing healthcare costs. This study aimed to evaluate the pharmacokinetic (PK) bioequivalence and safety of a generic febuxostat formulation compared to the reference product in a healthy Chinese population, while also investigating the impact of food on drug absorption.
Methodology
The study followed a randomized, open-label, two-sequence, two-period crossover design involving 80 healthy Han Chinese volunteers (74 males, 6 females). Participants were divided into two cohorts to test the formulations under either fasting or fed (high-fat meal) conditions. A 7-day washout period separated the two treatment periods. Plasma concentrations of febuxostat were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Bioequivalence was assessed based on the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) for $C_{max}$, $AUC_{0-t}$, and $AUC_{0-\infty}$, with the regulatory acceptance range set at 80.00%–125.00%.
Pharmacokinetic Profile and Food Effect
The pharmacokinetic analysis revealed that food significantly influences the absorption of febuxostat. Under fed conditions, the peak plasma concentration ($C_{max}$) decreased by approximately 35%, and the total systemic exposure ($AUC_{0-\infty}$) was reduced by roughly 12% compared to fasting conditions. Additionally, the time to reach peak concentration ($T_{max}$) was delayed by approximately 0.67 hours. Despite these changes, the generic and reference formulations exhibited nearly identical responses to food intake, ensuring that the "food effect" does not compromise the interchangeability of the drugs.
Pharmacokinetic parameters of test and reference febuxostat formulations under fasting and fed conditions.
The primary objective of the study was met, as the 90% CIs for the GMRs of all primary PK parameters fell entirely within the predefined 80–125% bioequivalence window for both fasting and fed states. This confirms that the generic formulation is pharmacokinetically interchangeable with Feburic®.
Statistical analysis of bioequivalence for primary pharmacokinetic parameters, showing all 90% CIs within the 80-125% range.
Safety assessments indicated that both formulations were well-tolerated. The incidence of adverse events (AEs) was higher in the fed group (25.0%) compared to the fasting group (12.8%), but all reported AEs were mild (Grade 1 or 2) and resolved without intervention. No serious adverse events (SAEs) or withdrawals due to AEs occurred during the trial, suggesting a comparable safety profile between the generic and reference products.
Conclusion
This randomized crossover study demonstrates that the generic febuxostat formulation is bioequivalent to the reference product, Feburic®, in healthy Chinese subjects under both fasting and fed conditions. While a high-fat meal alters the PK profile of febuxostat, the effect is consistent across both formulations, supporting the clinical use of the generic drug regardless of meal timing. These findings provide robust evidence for the generic as a cost-effective and clinically equivalent alternative for managing gout in the Chinese population.
Summary updated
Abstract
<title>Abstract</title> <bold>Purpose</bold> Febuxostat, a xanthine oxidase inhibitor, is a first-line treatment for gout with hyperuricemia. This study evaluated the pharmacokinetic (PK) bioequivalence, safety profile, and food effects of a generic febuxostat formulation compared to the reference product (Feburic®) in healthy Chinese volunteers <bold>Patients and Methods</bold> In this randomized, open-label, two-sequence, two-period crossover trial, 80 participants (74 males, 6 females) received single 40 mg doses of both test and reference formulations under fasting and fed conditions, separated by a 7-day washout. Plasma concentrations were quantified using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS). Primary endpoints included peak plasma concentration (C<sub>max</sub>), area under the plasma concentration-time curve from time zero to the last time quantifiable time point (AUC<sub>0 − t</sub> ), and area under the plasma concentration-time curve from time zero to infinity (AUC<sub>0−∞</sub>), with bioequivalence determined using 90% confidence intervals (CIs) for geometric mean ratios (GMRs). <bold>Results</bold> All 90% CIs for GMRs fell within the 80–125% bioequivalence range (fasting: AUC<sub>0 − t</sub> 99.08-104.28%, AUC<sub>0−∞</sub> 98.73-103.84%, C<sub>max</sub> 92.87-112.14%; fed: AUC<sub>0 − t</sub> 101.16-106.21%, AUC<sub>0−∞</sub> 101.13-105.94%, C<sub>max</sub> 91.72-105.07%). High-fat meals delayed T<sub>max</sub> by 0.67 h (<italic>P</italic> < 0.05) and reduced systemic exposure (C<sub>max</sub> by ~ 35%, AUC<sub>0−∞</sub> by ~ 12%). Adverse event incidence was 12.8% (fasting) and 25.0% (fed), with no serious adverse events reported. <bold>Conclusion</bold> The generic febuxostat formulation demonstrated PK equivalence to Feburic® under both fasting and fed conditions, with comparable safety profiles. The observed food effects, while statistically significant, support flexible administration without meal restrictions, positioning this generic as a clinically equivalent, cost-effective alternative for gout management. <bold>Clinical Trial Registration: </bold>This study was prospectively registered (Registration No. CTR20233483; First Public Release Date: 1 November 2023) in the Chinese Clinical Trial Registration Platform (http://www.chinadrugtrials.org.cn), a registry recognized by the Chinese National Medical Products Administration (NMPA). The trial was conducted from 28 November 2023 to 26 December 2023.
BibTeX
@inproceedings{wang2025bioequivalence,
author = {Fengling Wang and Xi Ye and Fan Li and H. Kong and Minjie Liao and Min‐Yen Kan and Juxiang Zhuang and Angeng Wang and Xiangyun Meng},
title = {{Bioequivalence Evaluation of Generic Febuxostat versus Feburic ® in Healthy Chinese Subjects: A Randomized Crossover Study}},
booktitle = {Research Square},
year = {2025},
doi = {10.21203/rs.3.rs-6492168/v1},
}